Clinical Research Directory
Browse clinical research sites, groups, and studies.
Characterizing the Use of Ofatumumab in a Real World Setting
Sponsor: Novartis Pharmaceuticals
Summary
This is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes.
Official title: Secondary Use of Data Study Characterizing Kesimpta (Ofatumumab) Onboarding and Utilization in RMS Patients Using MSGo, With a Non-interventional Primary Use of Data Sub-study Comparing Patient Reported Outcomes Relative to Clinical Outcomes (EAFToS)
Key Details
Gender
All
Age Range
18 Years - 120 Years
Study Type
OBSERVATIONAL
Enrollment
103
Start Date
2022-12-08
Completion Date
2026-02-06
Last Updated
2026-07-31
Healthy Volunteers
No
Conditions
Interventions
ofatumumab
There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.
Locations (7)
Novartis Investigative Site
Concord, New South Wales, Australia
Novartis Investigative Site
Southport, Queensland, Australia
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Heidelberg, Australia
Novartis Investigative Site
St Leonards, Australia